PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works

Restoring function in exhausted CD8 T cells during chronic viral infection

Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 3,960 · see citing works

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · see citing works

Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,259 · see citing works

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967 · see citing works

Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor

Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · see citing works

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680 · see citing works

CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms

Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931 · see citing works

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874 · see citing works

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes

Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589 · see citing works

Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction

Trautmann, L., Janbazian, L., Chomont, N., Said, E. A., Gimmig, S., Bessette, B., Boulassel, M.-R., Delwart, E., Sepulveda, H., Balderas, R. S., et al. (2006) · Nature Medicine · doi:10.1038/nm1482 · Cited by 1,565 · see citing works

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

Pulè, M. A., Savoldo, B., Myers, G. D., Rössig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195 · see citing works

Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer

Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S., Enomoto, K., Yagita, H., Azuma, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2746 · Cited by 889 · see citing works

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406351101 · Cited by 776 · see citing works

PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772 · see citing works

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

Till, B. G., Jensen, M. C., Wang, J., Chen, E., Wood, B. L., Greisman, H. A., Qian, X., James, S. E., Raubitschek, A. A., Forman, S. J., et al. (2008) · Blood · doi:10.1182/blood-2007-12-128843 · Cited by 721 · see citing works

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

Berger, R., Rotem‐Yehudar, R., Slama, G., Landes, S., Kneller, A., Leiba, M., Koren‐Michowitz, M., Shimoni, A., & Nagler, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4079 · Cited by 680 · see citing works

Biochemical characterization of a gamma interferon-inducible cytokine (IP-10)

Luster, A., & Ravetch, J. (1987) · Journal of Experimental Medicine · doi:10.1084/jem.166.4.1084 · Cited by 676 · see citing works

Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma

Hino, R., Kabashima, K., Kato, Y., Yagi, H., Nakamura, M., Honjo, T., Okazaki, T., & TOKURA, Y. (2010) · Cancer · doi:10.1002/cncr.24899 · Cited by 668 · see citing works

Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy

Blank, C. U., Gajewski, T. F., & Mackensen, A. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0593-x · Cited by 634 · see citing works

PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell Carcinoma

Thompson, R. H., Dong, H., Lohse, C. M., Leibovich, B. C., Blute, M. L., Cheville, J. C., & Kwon, E. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2599 · Cited by 569 · see citing works

Establishment of NOD- Pdcd1 -/- mice as an efficient animal model of type I diabetes

Wang, J., Yoshida, T., Nakaki, F., Hiai, H., Okazaki, T., & Honjo, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505497102 · Cited by 436 · see citing works

618: Costimulatory B7-H1 In Renal Cell Carcinoma Patients: Indicator of Tumor Aggressiveness and Potential Therapeutic Target

Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2005) · The Journal of Urology · doi:10.1016/s0022-5347(18)34858-4 · Cited by 386 · see citing works

The role of the PD‐1 pathway in autoimmunity and peripheral tolerance

Fife, B. T., & Pauken, K. E. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05919.x · Cited by 355 · see citing works

Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma.

Fisher, B., Packard, B. S., Read, E. J., Carrasquillo, J. A., Carter, C. S., Topalian, S. L., Yang, J., Yolles, P., Larson, S. M., & Rosenberg, S. A. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.2.250 · Cited by 327 · see citing works

Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma

Karim, R., Jordanova, E. S., Piersma, S. J., Kenter, G. G., Chen, L., Boer, J. M., Melief, C. J. M., & van der Burg, S. H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1652 · Cited by 250 · see citing works

Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer

Zhang, Y., Huang, S., Gong, D., Qin, Y., & Shen, Q. (2010) · Cellular and Molecular Immunology · doi:10.1038/cmi.2010.28 · Cited by 243 · see citing works

Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses

Peng, W., Ye, Y., Rabinovich, B. A., Liu, C., Lou, Y., Zhang, M., Whittington, M., Yang, Y., Overwijk, W. W., Lizee, G. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0712 · Cited by 222 · see citing works

In Vivo Distribution of Adoptively Transferred Indium- 111- Labeled Tumor Infiltrating Lymphocytes and Peripheral Blood Lymphocytes in Patients With Metastatic Melanoma

Griffith, K. D., Read, E. J., Carrasquillo, J. A., Carter, C. S., Yang, J. C.-H., Fisher, B., Aebersold, P. M., Packard, B. S., Yu, M. Y., & Rosenberg, S. A. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.22.1709 · Cited by 182 · see citing works

Anti‐PD‐1 synergizes with cyclophosphamide to induce potent anti‐tumor vaccine effects through novel mechanisms

Mkrtichyan, M., Najjar, Y. G., Raulfs, E. C., Abdalla, M. Y., Samara, R. N., Rotem‐Yehudar, R., Cook, L., & Khleif, S. N. (2011) · European Journal of Immunology · doi:10.1002/eji.201141639 · Cited by 144 · see citing works

Adoptive Cell Therapy for Patients with Melanoma, Using Tumor-Infiltrating Lymphocytes Genetically Engineered to Secrete Interleukin-2

Heemskerk, B., Liu, K., Dudley, M. E., Johnson, L. A., Kaiser, A., Downey, S. G., Zheng, Z., Shelton, T. E., Matsuda, K. M., Robbins, P. F., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.0171 · Cited by 136 · see citing works

Blockade of B7-H1 on Macrophages Suppresses CD4+ T Cell Proliferation by Augmenting IFN-γ-Induced Nitric Oxide Production

Yamazaki, T., Akiba, H., Koyanagi, A., Azuma, M., Yagita∥, H., & Okumura, K. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1586 · Cited by 136 · see citing works

Improving Antitumor Immune Responses by Circumventing Immunoregulatory Cells and Mechanisms

Lizee, G. A., Radvanyi, L. G., Overwijk, W. W., & Hwu, P. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0944 · Cited by 108 · see citing works

Early T Cell Signalling Is Reversibly Altered in PD-1+ T Lymphocytes Infiltrating Human Tumors

Renault, S., Fouquet, S., Chapon, M., Salmon, H., Régnier, F., Labroquère, K., Badoual, C., Damotte, D., Validire, P., Maubec, E., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017621 · Cited by 87 · see citing works

Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes

Chapon, M., Randriamampita, C., Maubec, E., Badoual, C., Fouquet, S., Wang, S.-F., Marinho, E., Farhi, D., Garcette, M., Jacobelli, S., et al. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.30 · Cited by 86 · see citing works

Development of Adoptive Cell Therapy for Cancer: A Clinical Perspective

Hawkins, R. E., Gilham, D. E., Debets, R., Eshhar, Z., Taylor, N. N., Abken, H., & Schumacher, T. N. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.086 · Cited by 79 · see citing works

Combination of lentivector immunization and low‐dose chemotherapy or PD‐1/PD‐L1 blocking primes self‐reactive T cells and induces anti‐tumor immunity

Sierro, S. R., Donda, A., Perret, R., Guillaume, P., Yagita∥, H., Lévy, F., & Romero, P. J. (2011) · European Journal of Immunology · doi:10.1002/eji.201041235 · Cited by 75 · see citing works

Blockade of Programmed Death-1 Pathway Rescues the Effector Function of Tumor-Infiltrating T Cells and Enhances the Antitumor Efficacy of Lentivector Immunization

Zhou, Q., Xiao, H., Liu, Y., Peng, Y., Yuan, H., Yagita∥, H., Chandler, P., Munn, D. H., Mellor, A. L., Fu, N., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001821 · Cited by 62 · see citing works

A New Approach to Simultaneously Quantify Both TCR α- and β-Chain Diversity after Adoptive Immunotherapy

Zhang, M., Maiti, S. N., Bernatchez, C., Huls, H. M., Rabinovich, B. A., Champlin, R. E., Vence, L. M., Hwu, P., Radvanyi, L. G., & Cooper, L. J. N. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3234 · Cited by 21 · see citing works

Effect of clinical status and previous treatment of melanoma patients on expansion of TIL for adoptive T-cell therapy

Peddareddigari, V. G. R., MILLER, P. W., Nebiyou, B. B., Overwijk, W. W., Ross, M. I., Lee, J., Gershenwald, J. E., Prieto, V. G., Hwu, P., & Radvanyi, L. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3021 · Cited by 1 · see citing works

Oncology meets immunology: the cancer-immunity cycle.

Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · see citing works

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · see citing works

CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy

Tokunaga, R., Zhang, W., Naseem, M., Puccini, A., Berger, M. D., Soni, S., McSkane, M., Baba, H., & Lenz, H.-J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.007 · Cited by 1,627 · see citing works

IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy

Ivashkiv, L. B. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0029-z · Cited by 1,374 · see citing works

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360 · see citing works

Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy

Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300 · see citing works

Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion

Castro, F., Cardoso, A. P., Gonçalves, R. M., Serre, K., & Oliveira, M. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00847 · Cited by 1,224 · see citing works

Overcoming T cell exhaustion in infection and cancer

Pauken, K. E., & Wherry, E. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.008 · Cited by 1,178 · see citing works

Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate

(2017) · doi:10.1158/1078-0432.ccr-16-3133 · Cited by 831 · see citing works

Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade

House, I. G., Savas, P., Lai, J., Chen, A. X. Y., Oliver, A. J., Teo, Z. L., Todd, K. L., Henderson, M. A., Giuffrida, L., Petley, E. V., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1868 · Cited by 790 · see citing works

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Ferrara, R., Mezquita, L., Texier, M., Lahmar, J., Audigier-Valette, C., Tessonnier, L., Mazieres, J., Zalcman, G., Brosseau, S., Le Moulec, S., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3676 · Cited by 720 · see citing works

Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

John, L. B., Devaud, C., Duong, C. P. M., Yong, C. S. M., Beavis, P. A., Haynes, N. M., Chow, M. T., Smyth, M. J., Kershaw, M. H., & Darcy, P. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0458 · Cited by 699 · see citing works

Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity

Wang, L.-C. S., Lo, A., Scholler, J., Sun, J., Majumdar, R. S., Kapoor, V., Antzis, M., Cotner, C. E., Johnson, L. A., Durham, A. C., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0027 · Cited by 653 · see citing works

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

Kleffel, S., Posch, C., Barthel, S. R., Mueller, H., Schlapbach, C., Guenova, E., Elco, C. P., Lee, N., Juneja, V. R., Zhan, Q., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.052 · Cited by 648 · see citing works

Key chemokines direct migration of immune cells in solid tumors

Kohli, K., Pillarisetty, V. G., & Kim, T. S. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00303-x · Cited by 583 · see citing works

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade

Schmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassará, A., Wyser Rmili, C., Kiialainen, A., Kienast, Y., Mueller, H.-J., Ooi, C.-H., Laoui, D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9670 · Cited by 582 · see citing works

Immune checkpoints and their inhibition in cancer and infectious diseases

Dyck, L., & Mills, K. H. G. (2017) · European Journal of Immunology · doi:10.1002/eji.201646875 · Cited by 541 · see citing works

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons

Naimi, A., Mohammed, R. N., Raji, A., Chupradit, S., Yumashev, A. V., Suksatan, W., Shalaby, M. N., Thangavelu, L. P., Kamrava, S., Shomali, N., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00854-y · Cited by 526 · see citing works

Chemokines in Cancer

Chow, M. T., & Luster, A. D. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0160 · Cited by 491 · see citing works

Beyond immune checkpoint blockade: emerging immunological strategies

Kubli, S. P., Berger, T., Araújo, D. V., Siu, L. L., & Mak, T. W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00155-y · Cited by 460 · see citing works

Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs

Allard, B., Pommey, S., Smyth, M. J., & Stagg, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0545 · Cited by 459 · see citing works

Teaching an old dog new tricks: next-generation CAR T cells

Tokarew, N. J. A., Ogonek, J., Endres, S., von Bergwelt‐Baildon, M., & Kobold, S. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0325-1 · Cited by 444 · see citing works

PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease

Baruch, K., Deczkowska, A., Rosenzweig, N., Tsitsou-Kampeli, A., Sharif, A. M., Matcovitch-Natan, O., Kertser, A., David, E., Amit, I., & Schwartz, M. (2016) · Nature Medicine · doi:10.1038/nm.4022 · Cited by 425 · see citing works

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis

Dahan, R., Sega, E. I., Engelhardt, J., Selby, M., Korman, A. J., & Ravetch, J. V. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.004 · Cited by 410 · see citing works

Trafficking of T Cells into Tumors

Slaney, C. Y., Kershaw, M. H., & Darcy, P. K. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2458 · Cited by 406 · see citing works

Recurrent glioma clinical trial, CheckMate-143: the game is not over yet

Filley, A. C., Henriquez, M. A., & Dey, M. (2017) · Oncotarget · doi:10.18632/oncotarget.21586 · Cited by 389 · see citing works

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

Li, X., Shao, C., Shi, Y., & Han, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0578-4 · Cited by 385 · see citing works

Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy

Lim, S. Y., Lee, J. H., Gide, T. N., Menzies, A. M., Guminski, A., Carlino, M. S., Breen, E. J., Yang, J. Y. H., Ghazanfar, S., Kefford, R. F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2795 · Cited by 381 · see citing works

BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice

Liu, C., Peng, W., Xu, C., Lou, Y., Zhang, M., Wargo, J. A., Chen, J. Q., Li, H. S., Watowich, S. S., Yang, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1626 · Cited by 379 · see citing works

Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment

Nicolás‐Boluda, A., Vaquero, J., Vimeux, L., Guilbert, T., Ghamry-Barrin, S., Kantari‐Mimoun, C., Ponzo, M., Renault, G., Deptuła, P., Pogoda, K., et al. (2021) · eLife · doi:10.7554/elife.58688 · Cited by 371 · see citing works

Mechanisms regulating T-cell infiltration and activity in solid tumors

Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369 · see citing works

Interferon gamma in cancer immunotherapy

Ni, L., & Lu, J. (2018) · Cancer Medicine · doi:10.1002/cam4.1700 · Cited by 360 · see citing works

Hyperprogressive disease: recognizing a novel pattern to improve patient management

Champiat, S., Ferrara, R., Massard, C., Besse, B., Marabelle, A., Soria, J., & Ferté, C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0111-2 · Cited by 360 · see citing works

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

Zheng, H., Zhao, W., Yan, C., Watson, C. C., Massengill, M. T., Xie, M., Massengill, C., Noyes, D. R., Martinez, G. V., Afzal, R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2584 · Cited by 339 · see citing works

Development of Immunotherapy Combination Strategies in Cancer

Yap, T. A., Parkes, E. E., Peng, W., Moyers, J. T., Curran, M. A., & Tawbi, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1209 · Cited by 336 · see citing works

Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses

Beavis, P. A., Milenkovski, N., Henderson, M. A., John, L. B., Allard, B., Loi, S., Kershaw, M. H., Stagg, J., & Darcy, P. K. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0211 · Cited by 331 · see citing works

CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas

Flores‐Toro, J., Luo, D., Gopinath, A., Sarkisian, M. R., Campbell, J. J., Charo, I. F., Singh, R., Schall, T. J., Datta, M., Jain, R. K., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1910856117 · Cited by 326 · see citing works

Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40

Messenheimer, D. J., Jensen, S. M., Afentoulis, M. E., Wegmann, K. W., Feng, Z., Friedman, D. J., Gough, M. J., Urba, W. J., & Fox, B. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2677 · Cited by 319 · see citing works

Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment

Hadrup, S. R., Donia, M., & Straten, P. T. (2012) · Cancer Microenvironment · doi:10.1007/s12307-012-0127-6 · Cited by 309 · see citing works

Migrating into the tumor: a roadmap for T cells

van der Woude, L. L., Gorris, M. A. J., Halilovic, A., Figdor, C. G., & de Vries, I. J. M. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.09.006 · Cited by 307 · see citing works

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Choueiri, T. K., Fishman, M. N., Escudier, B., McDermott, D. F., Drake, C. G., Kluger, H., Stadler, W. M., Perez-Gracia, J. L., McNeel, D. G., Curti, B., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2839 · Cited by 295 · see citing works

TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer

Park, B. V., Freeman, Z. T., Ghasemzadeh, A., Chattergoon, M. A., Rutebemberwa, A., Steigner, J., Winter, M. E., Huynh, T. V., Sebald, S. M., Lee, S.-J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1347 · Cited by 287 · see citing works

Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?

Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3498 · Cited by 267 · see citing works

Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation

Bald, T., Landsberg, J., Lopez-Ramos, D., Renn, M., Glodde, N., Jansen, P., Gaffal, E., Steitz, J., Tolba, R. H., Kalinke, U., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0458 · Cited by 256 · see citing works

Interferons and Their Stimulated Genes in the Tumor Microenvironment

Cheon, H., Borden, E. C., & Stark, G. R. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.02.002 · Cited by 250 · see citing works

PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer

Kansy, B., Concha‐Benavente, F., Srivastava, R. M., Jie, H.-B., Shayan, G., Lei, Y. L., Moskovitz, J. M., Moy, J. D., Li, J., Brandau, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3167 · Cited by 250 · see citing works

Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor

Mittal, D., Young, A., Stannard, K. A., Yong, M. C. R., Teng, M. W. L., Allard, B., Stagg, J., & Smyth, M. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0957 · Cited by 243 · see citing works

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

Selby, M., Engelhardt, J., Johnston, R. J., Lu, L.-S., Han, M., Thudium, K. B., Yao, D., Quigley, M. M., Valle, J., Wang, C., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161779 · Cited by 230 · see citing works

The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies

Sorkhabi, A. D., Khosroshahi, L. M., Sarkesh, A., Mardi, A., Aghebati‐Maleki, A., Maleki, L. A., & Baradaran, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113882 · Cited by 215 · see citing works

Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer

Fong, L. H., Carroll, P. R., WEINBERG, V. K., Chan, S. E., Lewis, J., Corman, J. M., Amling, C. L., Stephenson, R. A., Simko, J. P., Sheikh, N. A., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju268 · Cited by 212 · see citing works

Anti–PD-1/anti–CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8 + T cell trafficking

Taggart, D., Andreou, T., Scott, K. J., Williams, J. M., Rippaus, N., Brownlie, R. J., Ilett, E. J., Salmond, R. J., Melcher, A. A., & Lorger, M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714089115 · Cited by 209 · see citing works

Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy

Devaud, C., John, L. B., Westwood, J. A., Darcy, P. K., & Kershaw, M. H. (2013) · OncoImmunology · doi:10.4161/onci.25961 · Cited by 207 · see citing works

Immune dysregulation in cancer patients developing immune-related adverse events

Khan, S., Khan, S. A., Luo, X., Fattah, F. J., Saltarski, J. M., Gloria-McCutchen, Y., Lü, R., Xie, Y., Li, Q., Wakeland, E. K., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0155-1 · Cited by 194 · see citing works

Vaccines targeting helper T cells for cancer immunotherapy

Melssen, M. M., & Slingluff, C. L. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.07.004 · Cited by 193 · see citing works

Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration

Gordón‐Alonso, M., Hirsch, T., Wildmann, C., & van der Bruggen, P. (2017) · Nature Communications · doi:10.1038/s41467-017-00925-6 · Cited by 184 · see citing works

Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis

Qiao, J., Liu, Z., Dong, C., Luan, Y., Zhang, A., Moore, C., Fu, K., Peng, J., Wang, Y., Ren, Z., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.005 · Cited by 179 · see citing works

Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway

Lee, J., Ahn, E., Kissick, H. T., & Ahmed, R. (2015) · Forum on Immunopathological Diseases and Therapeutics · doi:10.1615/forumimmundisther.2015014188 · Cited by 165 · see citing works

Pseudoprogression and hyperprogression after checkpoint blockade

Wang, Q., Gao, J., & Wu, X. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.03.018 · Cited by 162 · see citing works

IFNγ-mediated repression of system xc− drives vulnerability to induced ferroptosis in hepatocellular carcinoma cells

Kong, R., Wang, N., Han, W., Bao, W., & Lu, J. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.3ma1220-815rrr · Cited by 162 · see citing works

Autocrine Complement Inhibits IL10-Dependent T-cell–Mediated Antitumor Immunity to Promote Tumor Progression

Wang, Y., Sun, S., Liu, Q., Yu, Y., Guo, J., Wang, K., Xing, B., Zheng, Q., Campa, M. J., Patz, E. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1412 · Cited by 160 · see citing works

Vitiligo-like lesions occurring in patients receiving anti-programmed cell death–1 therapies are clinically and biologically distinct from vitiligo

Larsabal, M., Marti, A., Jacquemin, C., Rambert, J., Thiolat, D., Dousset, L., Taı̈eb, A., Dutriaux, C., Prey, S., Boniface, K., et al. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.10.044 · Cited by 159 · see citing works

Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment

Peske, J. D., Woods, A. B., & Engelhard, V. H. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.05.001 · Cited by 159 · see citing works

Enhancing Tumor T Cell Infiltration to Enable Cancer Immunotherapy

Zhang, J., Endres, S., & Kobold, S. (2019) · Immunotherapy · doi:10.2217/imt-2018-0111 · Cited by 156 · see citing works

Accumulation of Memory Precursor CD8 T Cells in Regressing Tumors following Combination Therapy with Vaccine and Anti-PD-1 Antibody

Karyampudi, L., Lamichhane, P., Scheid, A. D., Kalli, K. R., Shreeder, B., Krempski, J. W., Behrens, M. D., & Knutson, K. L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2564 · Cited by 154 · see citing works

Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy

Yao, H., Wang, H., Li, C., Fang, J., & Xu, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01774 · Cited by 154 · see citing works

Chemoattractant Receptors BLT1 and CXCR3 Regulate Antitumor Immunity by Facilitating CD8+ T Cell Migration into Tumors

Chheda, Z. S., Sharma, R. K., Jala, V. R., Luster, A. D., & Haribabu, B. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502376 · Cited by 153 · see citing works

CXCL10 Triggers Early Microglial Activation in the Cuprizone Model

Clarner, T., Janssen, K., Nellessen, L., Stangel, M., Skripuletz, T., Krauspe, B., Hess, F.-M., Denecke, B., Beutner, C., Linnartz-Gerlach, B., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401459 · Cited by 150 · see citing works

Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells

Moreno, B. H., Zaretsky, J. M., García-Díaz, Á., Tsoi, J., Parisi, G., Robert, L., Meeth, K. M., Ndoye, A., Bosenberg, M., Weeraratna, A. T., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0060 · Cited by 146 · see citing works

Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells

Sætersmoen, M., Hammer, Q., Valamehr, B. B., Kaufman, D. S., & Malmberg, K. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0721-x · Cited by 144 · see citing works

Current Advances in T-Cell-Based Cancer Immunotherapy

Wang, M., Yin, B., Wang, H. Y., & Wang, R. (2014) · Immunotherapy · doi:10.2217/imt.14.86 · Cited by 141 · see citing works

The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors

Wang, M., Zhai, X., Li, J., Guan, J., Xu, S., Li, Y., & Zhu, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670391 · Cited by 141 · see citing works

Enhancement of T cell recruitment and infiltration into tumours

Oelkrug, C., & Ramage, J. M. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12382 · Cited by 140 · see citing works

Spatial and single-cell transcriptomics decipher the cellular environment containing HLA-G+ cancer cells and SPP1+ macrophages in colorectal cancer

Ozato, Y., Kojima, Y., Kobayashi, Y., Hisamatsu, Y., Toshima, T., Yonemura, Y., Masuda, T., Kagawa, K., Goto, Y., Utou, M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2022.111929 · Cited by 139 · see citing works

Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy

Swart, M., Verbrugge, I., & Beltman, J. B. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00233 · Cited by 137 · see citing works

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

Buqué, A., Bloy, N., Aranda, F., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Marabelle, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008814 · Cited by 130 · see citing works

Immune Checkpoint Protein Inhibition for Cancer: Preclinical Justification for CTLA-4 and PD-1 Blockade and New Combinations

Baksh, K. A., & Weber, J. S. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.015 · Cited by 130 · see citing works

Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?

Hilmi, M., Bartholin, L., & Neuzillet, C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i20.2137 · Cited by 124 · see citing works

Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma

Jing, W., Gershan, J. A., Weber, J. J., Tlomak, D., McOlash, L., Sabatos-Peyton, C. A., & Johnson, B. D. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0043-z · Cited by 119 · see citing works

Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy

Shi, L. Z., Fu, T., Guan, B., Chen, J., Blando, J. M., Allison, J. P., Xiong, L., Subudhi, S. K., Gao, J., & Sharma, P. (2016) · Nature Communications · doi:10.1038/ncomms12335 · Cited by 111 · see citing works

Role of T Cell Receptor Affinity in the Efficacy and Specificity of Adoptive T Cell Therapies

Stone, J. D., & Kranz, D. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00244 · Cited by 110 · see citing works

Immunotherapy in CNS cancers: the role of immune cell trafficking

Ratnam, N. M., Gilbert, M. R., & Giles, A. J. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy084 · Cited by 110 · see citing works

Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets

Zhong, Z., Vong, C. T., Chen, F., Tan, H., Zhang, C., Wang, N., Cui, L., Wang, Y., & Feng, Y. (2022) · Medicinal Research Reviews · doi:10.1002/med.21876 · Cited by 110 · see citing works

Harnessing the Power of the Immune System Via Blockade of PD-1 and PD-L1: A Promising New Anticancer Strategy

Reiss, K. A., Forde, P. M., & Brahmer, J. R. (2014) · Immunotherapy · doi:10.2217/imt.14.9 · Cited by 109 · see citing works

Tumor‐specific CD 4+ T cells maintain effector and memory tumor‐specific CD 8+ T cells

Church, S., Jensen, S. M., Antony, P. A., Restifo, N. P., & Fox, B. A. (2013) · European Journal of Immunology · doi:10.1002/eji.201343718 · Cited by 109 · see citing works

Clinical application of genetically modified T cells in cancer therapy

Kershaw, M., Westwood, J. A., Slaney, C., & Darcy, P. (2014) · Clinical & Translational Immunology · doi:10.1038/cti.2014.7 · Cited by 117 · see citing works

Mechanisms of Drug Resistance in Melanoma

Winder, M. L., & Virós, A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_17 · Cited by 108 · see citing works

Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic

Duong, C. P. M., Yong, C. S. M., Kershaw, M. H., Slaney, C. Y., & Darcy, P. K. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2014.12.009 · Cited by 107 · see citing works

Low CD8+ T Cell Infiltration and High PD-L1 Expression Are Associated with Level of CD44+/CD133+ Cancer Stem Cells and Predict an Unfavorable Prognosis in Pancreatic Cancer

Hou, Y., Chao, Y., Hsieh, M.-H., Tung, H., Wang, H., & Shan, Y. (2019) · Cancers · doi:10.3390/cancers11040541 · Cited by 107 · see citing works

Application of genetically engineered Salmonella typhimurium for interferon-gamma–induced therapy against melanoma

Yoon, W., Park, Y. C., Kim, J. S., Chae, Y. S., Byeon, J. H., Min, S., Park, S., Yoo, Y., Park, Y., & Kim, B. M. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.010 · Cited by 106 · see citing works

mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients

Bidram, M., Zhao, Y., Shebardina, N. G., Baldin, A. V., Bazhin, A. V., Ganjalikhany, M. R., Zamyatnin, A. A., & Ganjalıkhani-Hakemi, M. (2021) · Vaccines · doi:10.3390/vaccines9101060 · Cited by 106 · see citing works

Hyperprogression as a distinct outcome after immunotherapy

Fuentes‐Antrás, J., Provencio, M., & Díaz‐Rubio, E. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.07.006 · Cited by 101 · see citing works

STAT3 in CD8+ T Cells Inhibits Their Tumor Accumulation by Downregulating CXCR3/CXCL10 Axis

Yue, C., Shen, S., Deng, J., Priceman, S. J., Li, W., Huang, A., & Yu, H. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0014 · Cited by 100 · see citing works

Regulation and targeting of SREBP-1 in hepatocellular carcinoma

Su, F., & Koeberle, A. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10156-5 · Cited by 100 · see citing works

Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma

Atanackovic, D., Luetkens, T., & Kröger, N. M. (2013) · Leukemia · doi:10.1038/leu.2013.310 · Cited by 99 · see citing works

Plug-and-Play Nanorization of Coarse Black Phosphorus for Targeted Chemo-photoimmunotherapy of Colorectal Cancer

Ou, W., Byeon, J. H., Thapa, R. K., Ku, S., Yong, C. S., & Kim, J. O. (2018) · ACS Nano · doi:10.1021/acsnano.8b04658 · Cited by 97 · see citing works

Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk

Salerno, E. P., Bedognetti, D., Mauldin, I. S., Deacon, D. H., Shea, S. M., Pinczewski, J., Obeid, J. M., Coukos, G., Wang, E., Gajewski, T. F., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1240857 · Cited by 96 · see citing works

STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity

Falahat, R., Perez-Villarroel, P., Mailloux, A. W., Zhu, G., Pilon-Thomas, S., Barber, G. N., & Mulé, J. J. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0229 · Cited by 95 · see citing works

Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer

Lu, J., Li, J., Lin, Z., Li, H., Lou, L., Ding, W., Ouyang, S., Wu, Y., Wen, Y., Chen, X., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216205 · Cited by 93 · see citing works

CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors

Filley, A. C., Henriquez, M. A., & Dey, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00453 · Cited by 91 · see citing works

Abstract 4385: PD-1 blockade enhances T-cell migration to tumor through induction of IFN-γ inducible chemokines

Peng, W., Liu, C., Xu, C., Chen, J., Lou, Y., Overwijk, W. W., Lizee, G. A., Yagita∥, H., & Hwu, P. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-4385

Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer

Peng, W., Lizee, G. A., & Hwu, P. (2013) · OncoImmunology · doi:10.4161/onci.22691 · Cited by 36 · see citing works

PD-1 blockade reverts motility arrest of transferred tumor-infiltrating CD8+ T cells in adoptive cell transfer immunotherapy (TUM7P.1014)

Mehta, G. U., Sukumar, M., McGavern, D. B., & Restifo, N. P. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.194.supp.142.3

Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner

Shi, L. Z., Goswami, S., Fu, T., Guan, B., Chen, J., Xiong, L., Zhang, J., Tang, D. N., Zhang, X., Vence, L. M., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0873 · Cited by 47 · see citing works

Impact of a New Fusion Receptor on PD-1–Mediated Immunosuppression in Adoptive T Cell Therapy

Kobold, S., Grassmann, S. A., Chaloupka, M., Lampert, C., Wenk, S., Kraus, F. B. T., Rapp, M., Duewell, P., Zeng, Y., Schmollinger, J. C., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv146 · Cited by 117 · see citing works